These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 37328635)

  • 1. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
    Landgren O; Nadeem O
    Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
    Zhao J; Ren Q; Liu X; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast.
    Costa LJ; Rodriguez-Otero P
    Adv Ther; 2024 Aug; 41(8):3017-3027. PubMed ID: 38642197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.
    Verkleij CPM; O'Neill CA; Broekmans MEC; Frerichs KA; Bruins WSC; Duetz C; Kruyswijk S; Baglio SR; Skerget S; Montes de Oca R; Zweegman S; Verona RI; Mutis T; van de Donk NWCJ
    Clin Cancer Res; 2024 Jul; 30(14):3006-3022. PubMed ID: 38687588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
    Kazandjian D; Kowalski A; Landgren O
    Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
    Tanenbaum B; Miett T; Patel SA
    Ann Hematol; 2023 Jan; 102(1):1-11. PubMed ID: 36462062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bispecific antibodies in multiple myeloma].
    Escure G; Manier S
    Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibodies in multiple myeloma treatment: A journey in progress.
    Cho SF; Yeh TJ; Anderson KC; Tai YT
    Front Oncol; 2022; 12():1032775. PubMed ID: 36330495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.
    Jourdes A; Cellerin E; Touzeau C; Harel S; Denis B; Escure G; Faure E; Jamard S; Danion F; Sonntag C; Ader F; Karlin L; Soueges S; Cazelles C; de La Porte des Vaux C; Frenzel L; Lanternier F; Brousse X; Cazaubiel T; Berger P; Collignon A; Blot M; Pieragostini A; Charles M; Chaleteix C; Redor A; Roland V; Cartau T; Macro M; Chalopin T; Vallet N; Perrot A; Martin-Blondel G;
    Clin Microbiol Infect; 2024 Jun; 30(6):764-771. PubMed ID: 38432433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
    Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
    N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
    Verkleij CPM; Broekmans MEC; van Duin M; Frerichs KA; Kuiper R; de Jonge AV; Kaiser M; Morgan G; Axel A; Boominathan R; Sendecki J; Wong A; Verona RI; Sonneveld P; Zweegman S; Adams HC; Mutis T; van de Donk NWCJ
    Blood Adv; 2021 Apr; 5(8):2196-2215. PubMed ID: 33890981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
    Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
    Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms.
    Lee H; Neri P; Bahlis NJ
    Blood; 2024 Mar; 143(13):1211-1217. PubMed ID: 38194680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
    Holstein SA; Grant SJ; Wildes TM
    J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
    Li X; Zhang P; Sun H; Han L; Jiang Z; Yu J
    Expert Opin Biol Ther; 2023; 23(12):1193-1195. PubMed ID: 37852928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting GPRC5D in multiple myeloma.
    Elemian S; Al Hadidi S
    Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment.
    Morè S; Corvatta L; Manieri VM; Morsia E; Poloni A; Offidani M
    Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.